Home  |  Contact

Cellosaurus SUP-B15/RI (CVCL_S642)

[Text version]

Cell line name SUP-B15/RI
Synonyms SUP-B15-RI
Accession CVCL_S642
Resource Identification Initiative To cite this cell line use: SUP-B15/RI (RRID:CVCL_S642)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
Derived from sampling site: Bone marrow.
Sequence variations
  • Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
Disease Childhood B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1 (NCIt: C68659)
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) (ORDO: Orphanet_585909)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0103 (SUP-B15)
Sex of cell Male
Age at sampling 9Y
Category Cancer cell line

PubMed=22285507; DOI=10.1016/j.leukres.2011.12.018
Xing H., Yang X., Liu T., Lin J., Chen X., Gong Y.
The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.
Leuk. Res. 36:509-513(2012)

Lin J., Xing H.-Y., Gong Y.-P., Yang X., Guo Y., Shan Q.-Q., Zhou R.-Q.
Multidrug resistant gene MDR1 contributes to development of imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line SUP-BS15RI.
Sichuan Da Xue Xue Bao Yi Xue Ban 43:657-660(2012)

Encyclopedic resources Wikidata; Q54970860
Polymorphism and mutation databases Cosmic; 1630018
Entry history
Entry creation03-Feb-2014
Last entry update23-Jun-2022
Version number11